United States: Senators Ask HHS To Step Up Scrutiny Of Pods Under Sunshine Act

On March 19, 2019, Senators Chuck Grassley (R-IA) and Ron Wyden (D-OR) of the Senate Finance Committee (“SFC”) wrote a letter (the “POD Letter”) to the HHS Office of Inspector General (“OIG”) and the Administrator of the Centers for Medicare and Medicaid Services (“CMS”) calling for increased scrutiny of the compliance by physician-owned distributors of implantable medical devices (“PODs”) with the reporting requirements of the Physician Payments Sunshine Act ( “Sunshine Act”).1 PODs have been less in the news since SFC’s last report on PODs in 2016. However, the POD Letter, together with recent report from the Medicare Payment Advisory Commission (“MedPAC”), demonstrates that Federal government scrutiny of the “inherently suspect” conflict-of-interest that inheres in the POD business model is far from over. The POD Letter also suggests that the Sunshine Act’s existing ownership and investment reporting obligations may be far broader than many PODs currently believe.

Background on Fraud and Abuse Concerns Regarding PODs

As detailed over more than a decade of Federal government attention, PODs purchase, or arrange for the purchase of, implantable medical devices ordered by their physician-owners for use in their own patient procedures. Regulators and members of Congress from both parties have long recognized the potential for patient and program harm that may result from giving physicians a financial interest in whether to perform an implant surgery, and which device to choose:

  • 2006: Assistant Inspector General (now OIG Chief Counsel) Gregory Demske testifies before Congress that “[PODs] raise substantial concerns that a physician’s return on investment . . . may influence the physician’s choice of device” and that “these ventures should be closely scrutinized.”2
  • 2011: SFC staff issues the first of two reports echoing these concerns, and members pen letters to OIG and CMS calling for an OIG investigation and requesting that CMS not inadvertently provide protection for PODs when drafting ownership disclosure requirements under the Sunshine Act.3
  • 2013: OIG issues Special Fraud Alert [on] Physician-Owned Entities (“SFA”) warning that PODs “produce substantial fraud and abuse risk and pose dangers to patient safety” and that PODs are “inherently suspect” under the Anti-Kickback Statute (“AKS”).4
  • 2013: Later that year OIG issues the first of two reports, concluding that PODs lead to an increase in spinal surgeries and do not reduce, and in some cases increase, costs of the procedures in which implants are used.5
  • 2015: OIG issues second report concluding that there is “limited transparency with regard to ownership information for PODs,” but that CMS’ implementation of the Sunshine Act may improve the information available. OIG also states that it will monitor CMS’s Sunshine Act database and determine how best to assess its impact on transparency.6
  • 2015: SFC holds a hearing on whether PODs are harmful to patients and payers of health care services.7
  • 2016: SFC staff issues its second report. Relying on evidence from its hearing and the 2013 OIG report, this one is highly critical, and concludes that PODs are likely to lead to overutilization, increased costs, and harm to patients.8 Especially pertinent to the POD Letter, the report also highlights that PODs operate with a lack of transparency and have taken steps to conceal their financial relationships, and encourages CMS to undertake increased enforcement of Sunshine Act requirements.
  • 2017: Detroit-area neurosurgeon is sentenced to almost 20 years in prison after pleading guilty to criminal health care fraud involving PODs and the spinal implant company Reliance Medical Systems LLC (“Reliance”). As part of his guilty plea, he admits that the financial incentives of PODs induced him to perform medically unnecessary procedures and that he purposefully concealed his ownership interest in the POD from hospital purchasers in his efforts to convince them to buy from the POD.9
  • 2018: MedPAC issues annual report to Congress and suggests ways in which policymakers can constrain risks posed by PODs. One suggestion is to require all PODs to report under the Open Payments program established by CMS (authorized by the Sunshine Act) by clarifying the definition of POD to prevent PODs with superficial variations in ownership and payment structures from being characterized as such.10

Apart from the Reliance cases, some of which are still pending, there has been little publicity about AKS enforcement against PODs. However, as the SFC’s 2016 Report noted, many large hospital systems have been adopting policies that constrain, and in some cases prohibit, purchasing from PODs.11

Enter the Sunshine Act

Citing the substantive concerns with PODs noted above, the Senators turn to the Sunshine Act as a method of curbing the negative impact of PODs. In addition to its provisions requiring that drug and medical device manufacturers report annually on payments and other transfers of value to physicians and teaching hospitals, the Sunshine Act also requires applicable group purchasing organizations (“AGPOs”) to report on their ownership and investment relationships with physicians and immediate family members. Recalling OIG’s 2015 undertaking to monitor POD transparency under the Sunshine Act, the Senators ask OIG and CMS to report by April 15th what actions they have taken. As of this writing, the agencies do not appear to have responded.

Scope of Sunshine Act AGPO Investment Disclosure Obligations

Importantly, the POD Letter suggests that the scope of the AGPO disclosure obligation under the Sunshine Act may be broader than many PODs currently assume. The POD Letter states that PODs “are a subset” of AGPOs, suggesting that all PODs are obligated to report their physician investors, regardless of how many customers they have.

There is support for this conclusion, which was advanced by commenters to the Sunshine Act regulations, in the statute and regulations.12 As the commenters pointed out, the Sunshine Act’s definition of AGPO differs fundamentally from the definition of “group purchasing organization” (“GPO”) set forth in the AKS safe harbor regulations, which define a GPO as a “purchasing agent for a group of individuals or entities . . . .”13  In contrast, the Sunshine Act defines an AGPO as “a group purchasing organization (as defined by the Secretary) that “purchases, arranges for, or negotiates the purchase of a covered drug, device, biological, or medical supply . . . .”14 Thus, the Sunshine Act definition expands the scope of activities that define an AGPO beyond purchasing agent to include entities that arrange for or negotiate a purchase.

CMS’s regulations mostly incorporate the statutory definition of AGPO, just adding a clarification to exclude purchases by end users.15 CMS largely agreed with the commenters, stating that it intended to include PODs in its definition of AGPO because it interpreted the term AGPO in the statute “to encompass not only more traditional GPOs that negotiate contracts for their members, but also entities [such as PODs] that purchase covered drugs, devices, biologicals, and medical supplies for resale or distribution to groups of individuals or entities.”16 While CMS declined to incorporate commenter suggestions to broaden the AGPO definition to encompass PODs that did not act on behalf of a group, it concluded that its definition “capture[d] as many PODs as possible, while still aligning with the statutory language.”17

Notably, CMS did not clarify in the rule when a “group” exists. Neither does CMS’s guidance on this point provide much helpful clarification, with its FAQs stating only that “a ‘group’ consists of two or more individuals and/or entities.”18

Consistent with the regulatory language and guidance, the Senators’ letter supports the interpretation that, as long as the POD is acting to “arrange for or negotiate” a purchase on behalf of more than one individual, the entity is acting on behalf of a “group” and is therefore an AGPO. Because a POD acts not only on behalf of the purchasing hospital or ASC, but also on behalf of the physician-owners who order the POD’s products, virtually all PODs that are not themselves manufacturers would meet this definition. Thus, without any change in current regulations, CMS could begin to address the Senators’ concerns by clarifying that a “group” for the purpose of an AGPO may consist of a single owner and a single purchaser or multiple physician owners of a POD. Similarly, CMS and OIG could use the audit and civil monetary penalty powers granted in the regulations to pursue this broader range of PODs.


The POD Letter’s call for action, coupled with its broad statement that all PODs should be reporting under the Sunshine Act, should be viewed at a minimum as raising the stakes for PODs and the doctors and hospitals that deal with them. We will have to see whether this portends a change in Sunshine Act reporting or enforcement, or other adverse attention to PODs.


1. 42 U.S.C. §§ 1320a-7h et seq.

2. Testimony of Gregory Demske, Assistant Inspector General for Legal Affairs, before the U.S. Senate Special Committee on Aging Examining the Relationship Between the Medical Device Industry and Physicians (February 27, 2008).

3. Letter from Senator Grassley et al. to OIG (June 9, 2011); Letter from Senator Grassley et al. to CMS (June 9, 2011).

4. Special Fraud Alert: Physician-Owned Entities, OIG (March 26, 2013).

5. Spinal Devices Supplied by Physician-Owned Distributors: Overview of Prevalence and Use, OIG (Oct. 2013).

6. Overlap Between Physician-Owned Hospitals and Physician-Owned Distributorships, OIG (Aug. 13, 2015).

7. Physician Owned Distributors: Are They Harmful to Patients and Payers, Full Committee Hearing, Senate Finance Committee, November 17, 2015.

8. Physician Owned Distributorships: An Update on Key Issues and Areas of Congressional Concern, Senate Finance Committee (May 10, 2016) (the "2016 Report").

9. Press Release, "Detroit-Area Neurosurgeon Sentenced to 235 Months in Prison for Role in $2.8 Million Health Care Fraud Scheme." Department of Justice (January 9, 2017).

10. Report to The Congress: Medicare and The Health Care Delivery System, MedPAC (June 15, 2018) at 158.

11. See 2016 Report at 20, stating that "[h]ospitals have implemented varied and unique strategies to protect themselves from PODs" and highlighting examples of hospital anti-POD policies.

12. See 78 Fed. Reg. 9458, 9493 (Feb. 8, 2013).

13. 42 C.F.R. § 1001.952(j) (emphasis added).

14. See 42 U.S.C. 1320a-7h(e) (emphasis added).

15. 42 C.F.R. § 403.902 (defining an AGPO as an entity that "[p]urchases, arranges for or negotiates the purchase of a covered drug, device, biological, or medical supply for a group of individuals or entities, but not solely for use by the entity itself.").

16. 78 Fed. Reg. at 9493.

17. 78 Fed. Reg. at 9493.

18. See FAQ #8368 of the Open Payments Frequently Asked Questions (FAQs) (last updated Jan. 18, 2019).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions